---
document_datetime: 2023-09-21 17:59:33
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/enzepi-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: enzepi-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.1323876
conversion_datetime: 2025-12-19 03:46:28.053113
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## Enzepi

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                           | Opinion/ Notification 1 issued on product   | Commission Decision Issued 2 / amended on no   | Product Information affected 3   | Summary                           |
|----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------|------------------------------------------------|----------------------------------|-----------------------------------|
| PSUSA/10522 /201612  | Periodic Safety Update EU Single assessment - pancreas powder (centrally authorised product only)                                               | 06/07/2017                                  | n/a                                            |                                  | PRAC Recommendation - maintenance |
| T/0001               | Marketing authorisation transfer from Aptalis Pharma SAS to Allergan Pharmaceuticals International Limited. Transfer of Marketing Authorisation | 09/08/2016                                  | 02/09/2016                                     | SmPC, Labelling and PL           |                                   |

<!-- image -->

Medicinal product no longer authorised

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->